The role of inflammasomes as central inflammatory hubs in Mycobacterium tuberculosis infection

Front Immunol. 2024 Sep 11:15:1436676. doi: 10.3389/fimmu.2024.1436676. eCollection 2024.

Abstract

Mycobacterium tuberculosis (Mtb) infection represents a global health problem and is characterized by formation of granuloma with a necrotic center and a systemic inflammatory response. Inflammasomes have a crucial role in the host immune response towards Mtb. These intracellular multi-protein complexes are assembled in response to pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs). Inflammasome platforms activate caspases, leading to the maturation of the proinflammatory cytokines interleukin (IL)-1 and 18 and the cleavage of gasdermin D (GSDMD), a pore-forming protein responsible for cytokine release and pyroptotic cell death. Recent in vitro and in vivo findings have highlighted the importance of inflammasome signaling and subsequent necrotic cell death in Mtb-infected innate immune cells. However, we are just beginning to understand how inflammasomes contribute to disease or to a protective immune response in tuberculosis (TB). A detailed molecular understanding of inflammasome-associated pathomechanisms may foster the development of novel host-directed therapeutics or vaccines with improved activity. In this mini-review, we discuss the regulatory and molecular aspects of inflammasome activation and the associated immunological consequences for Mtb pathogenesis.

Keywords: AIM2 inflammasome; Mycobacterium tuberculosis; NLRP3 inflammasome; drug resistance; gasdermin; inflammasome; interleukin-1; tuberculosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Host-Pathogen Interactions / immunology
  • Humans
  • Immunity, Innate
  • Inflammasomes* / immunology
  • Inflammasomes* / metabolism
  • Inflammation / immunology
  • Mycobacterium tuberculosis* / immunology
  • Signal Transduction / immunology
  • Tuberculosis* / immunology
  • Tuberculosis* / microbiology

Substances

  • Inflammasomes

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The author’s research is funded by the European Union Innovative Medicines Initiative 2 Joint Undertaking program grant no. 853989 (ERA4TB to JR), the German Federal Ministry of Education and Research (BMBF; grant IdEpiCo to JR); the German Research Council (DFG; CRC 1403 to JR), and the German Center for Infection Research (DZIF; TTU 02.814 and 02.913 to JR). ST and JR are supported by a research grant of the CMMC (B10), and ST by stipends from the Imhoff-Stiftung and the Koeln Fortune Program.